Smart Patients Get Smart Care™
The World’s Leading Authority for Chronic Lymphocytic Leukemia Patients
Blocking the B-cell receptor (BCR) with ibrutinib and other BTKi drugs has revolutionized care in CLL. PI3K inhibitors also block that same receptor and are remarkably effective in treating CLL. Join Dr. Ian Flinn who will explain how these treatments work, the common side effects, and what role they might play in the future.
At the annual meeting of the American Society of Hematology (ASH) 2020, Dr. John Pagel of the CLL Society Board of Directors interviewed Dr. Peter Hillmen, Professor of Experimental Hematology at the University of Leeds in the United Kingdom. They discussed updates to the phase II CLARITY trial which has been evaluating the efficacy of combination ibrutinib + venetoclax in patients with relapsed/refractory CLL.
At the annual meeting of the European Hematology Association (EHA) 2021, our own Dr. Brian Koffman interviewed Dr. Anthony Mato, Director of the CLL Program at Memorial Sloan Kettering Cancer Center. They discussed preliminary results from a clinical trial of pirtobrutinib (formerly LOXO-305) in a subset of patients with Richter’s transformation.
The short and most honest answer to most of the questions on vaccines, antibody responses, and masks is that we don’t know for those us with chronic lymphocytic leukemia.
Flow cytometry is the standard test to look for Measurable (Minimal) Residual Disease (MRD) in CLL and it can find one cancer cell in 10,000 by looking at the telltale combination
CLL Meets COVID Vaccines. Dr. Koffman shares what we know, what we don’t know and next steps here.
Bill Ludwig, 75, of Upper Deerfield Township passed away on Sunday, January 31, 2021 at the Hospital of the University of Pennsylvania where he had been hospitalized since December 1, 2020.
Below is the letter we received with the details for this remarkable COVID inspired program. It contains links to a downloadable file with a list of covered meds and Q+A.
This was a gutsy trial, a first of its kind head-to-head comparison between two Bruton Tyrosine Kinase (BTK) inhibitors, acalabrutinib and ibrutinib for bragging rights as to who was the best in class for treating chronic lymphocytic leukemia patients.
One click to our most popular content.
